Payment overview · 2025
General Payments
$818.59
41 reported records · 10 companies
Healthcare provider profile · identity verified
Ryan Stevenson, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · SAGINAW, MI · NPI 1861791964
Verified facts
What the public records show
CMS Open Payments records show Ryan Stevenson, D.O. received $818.59 in general payments during 2025 across 41 reported records.
ABBVIE INC. accounted for 62.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 581 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $508.00 | 62.1% | 19 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $153.43 | 18.7% | 13 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.73 | 3.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $24.37 | 3.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.52 | 2.9% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.60 | 2.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.15 | 2.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.02 | 2.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.46 | 1.9% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $14.31 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $818.59 | 41 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $502.81 | 18 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $98.35 | 8 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $82.95 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $82.11 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $36.22 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $28.73 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $24.37 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $24.37 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $23.52 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.15 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.46 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $14.31 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $5.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 157 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 116 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 581 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 56 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 120 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
137 | 33 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
157 | 49 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
120 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
157 | 49 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
116 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
82 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
581 | 143 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
56 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 863 | 257 |
| Losartan Potassium | Losartan Potassium | 680 | 195 |
| Atorvastatin Calcium | Atorvastatin Calcium | 664 | 192 |
| Levothyroxine Sodium | Levothyroxine Sodium | 616 | 163 |
| Ozempic | Semaglutide | 581 | 143 |
| Amlodipine Besylate | Amlodipine Besylate | 562 | 153 |
| Lisinopril | Lisinopril | 524 | 156 |
| Omeprazole | Omeprazole | 447 | 139 |
| Hydrochlorothiazide | Hydrochlorothiazide | 443 | 126 |
| Tramadol Hcl | Tramadol Hcl | 391 | 108 |
| Metformin Hcl Er | Metformin Hcl | 349 | 109 |
| Tamsulosin Hcl | Tamsulosin Hcl | 318 | 94 |
| Potassium Chloride | Potassium Chloride | 311 | 91 |
| Gabapentin | Gabapentin | 296 | 79 |
| Simvastatin | Simvastatin | 291 | 80 |
| Metoprolol Tartrate | Metoprolol Tartrate | 289 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 263 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 259 | 65 |
| Furosemide | Furosemide | 241 | 66 |
| Allopurinol | Allopurinol | 239 | 64 |
| Sertraline Hcl | Sertraline Hcl | 201 | 66 |
| Eliquis | Apixaban | 199 | 45 |
| Trazodone Hcl | Trazodone Hcl | 193 | 57 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 192 | 66 |
| Metformin Hcl | Metformin Hcl | 190 | 56 |
| Alprazolam | Alprazolam | 189 | 64 |
| Atenolol | Atenolol | 178 | 50 |
| Duloxetine Hcl | Duloxetine Hcl | 177 | 50 |
| Fluoxetine Hcl | Fluoxetine Hcl | 175 | 48 |
| Jardiance | Empagliflozin | 157 | 49 |
| Famotidine | Famotidine | 155 | 46 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 149 | 46 |
| Prednisone | Prednisone | 145 | 120 |
| Bupropion Xl | Bupropion Hcl | 143 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 137 | 38 |
| Farxiga | Dapagliflozin Propanediol | 137 | 33 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 132 | 82 |
| Finasteride | Finasteride | 128 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 126 | 52 |
| Montelukast Sodium | Montelukast Sodium | 126 | 37 |
| Glipizide Er | Glipizide | 124 | 42 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 124 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 121 | 23 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 120 | 34 |
| Celecoxib | Celecoxib | 118 | 41 |
| Mounjaro | Tirzepatide | 116 | 23 |
| Carvedilol | Carvedilol | 115 | 32 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 114 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 103 | 30 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 98 | 27 |
| Lovastatin | Lovastatin | 96 | 24 |
| Pregabalin | Pregabalin | 95 | 30 |
| Cephalexin | Cephalexin | 93 | 74 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 37 |
| Xarelto | Rivaroxaban | 92 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 91 | 36 |
| Temazepam | Temazepam | 91 | 22 |
| Ibuprofen | Ibuprofen | 87 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 85 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 23 |
| Ondansetron Odt | Ondansetron | 83 | 29 |
| Spironolactone | Spironolactone | 83 | 25 |
| Trulicity | Dulaglutide | 82 | 14 |
| Estradiol | Estradiol | 79 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 76 | 25 |
| Meloxicam | Meloxicam | 70 | 24 |
| Paroxetine Hcl | Paroxetine Hcl | 69 | 19 |
| Donepezil Hcl | Donepezil Hcl | 65 | 24 |
| Doxycycline Hyclate | Doxycycline Hyclate | 63 | 57 |
| Methocarbamol | Methocarbamol | 62 | 20 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 62 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 62 | 19 |
| Nystatin | Nystatin | 61 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 15 |
| Rybelsus | Semaglutide | 56 | 17 |
| Buspirone Hcl | Buspirone Hcl | 54 | 20 |
| Alendronate Sodium | Alendronate Sodium | 53 | 17 |
| Glipizide | Glipizide | 52 | 13 |
| Warfarin Sodium | Warfarin Sodium | 52 | 11 |
| Clonazepam | Clonazepam | 50 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 50 | 17 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 49 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 48 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 48 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 15 |
| Synthroid | Levothyroxine Sodium | 46 | 12 |
| Acyclovir | Acyclovir | 44 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | 12 |
| Azelastine Hcl | Azelastine Hcl | 44 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | 13 |
| Lorazepam | Lorazepam | 44 | suppressed |
| Nitroglycerin | Nitroglycerin | 44 | 24 |
| Aripiprazole | Aripiprazole | 43 | 17 |
| Fluconazole | Fluconazole | 42 | 31 |
| Diazepam | Diazepam | 41 | 17 |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | 13 |
| Valacyclovir | Valacyclovir Hcl | 36 | 26 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 35 | 16 |
| Bethanechol Chloride | Bethanechol Chloride | 34 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 34 | 13 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 34 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 33 | 15 |
| Eszopiclone | Eszopiclone | 31 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 29 |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 29 | 18 |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 26 | 12 |
| Invokana | Canagliflozin | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Bumetanide | Bumetanide | 23 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Folic Acid | Folic Acid | 22 | suppressed |
| Metronidazole | Metronidazole | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Lansoprazole | Lansoprazole | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Multaq | Dronedarone Hcl | 19 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Fluocinonide | Fluocinonide | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 16 | suppressed |
| Sulfasalazine | Sulfasalazine | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Brilinta | Ticagrelor | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 14 | suppressed |
| Captopril | Captopril | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Felodipine Er | Felodipine | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Mesalamine | Mesalamine | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Zolmitriptan | Zolmitriptan | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 12 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | 11 |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $818.59 · 41 records | ABBVIE INC. | AIRSUPRA, Auvelity, Cologuard Collection Kit, JARDIANCE, MOUNJARO, Ozempic, QULIPTA, REXULTI, Rybelsus, TRELEGY ELLIPTA, TRINTELLIX, UBRELVY, VRAYLAR, Wegovy, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error